Neurocrine Biosciences (NBIX) Tops Q4 EPS by 12c ; Offers Guidance

Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $1.69, $0.12 better than the analyst estimate of $1.57. Revenue for the quarter came in at $627.7 million versus the consensus estimate of $630.01 million.

GUIDANCE:

Neurocrine Biosciences sees FY2025 revenue of $2.5-2.6 billion, versus the consensus of $2.35 billion.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August